Viatris VTRS, a global healthcare company, is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, 2025.

Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of ...

Shares of Viatris Inc. VTRS advanced 1.19% to $11.06 Thursday, on what proved to be an all-around dismal trading session for ...